Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q3 2012
Oct 31, 2012 - GlobalData - 97 pages
Abstract Table of Contents Request Details Related
1 Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Industry Insights
3 Pharmaceuticals & Healthcare, Global, Deal Summary, Q3 2012
3.1 Pharmaceuticals & Healthcare, Global, Deals Analysis, Q3 2012
3.2 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, Q3 2012
3.3 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, Q3 2012
3.4 Pharmaceuticals & Healthcare, Global, Top Deals, Q3 2012
3.4.1 Aetna to Acquire Coventry Health Care, Provider of Healthcare Services, for up to $7.3 Billion
3.4.2 WellPoint Extends Antitrust Clearance Approval to Acquire Amerigroup for $4.9 Billion
3.4.3 Linde Completes Acquisition of Lincare, Provider of Respiratory Therapy Services, for $4.6 Billion
3.4.4 Valeant Pharma to Acquire Medicis Pharma, Developer of Treatment for Dermatology and Aesthetics Conditions, for up To $2.6 Billion
3.4.5 Health Care REIT to Acquire Sunrise Senior Living for $1.9 Billion
4 Pharmaceuticals & Healthcare, Global, Deals Summary, by Type
4.1 Pharmaceuticals & Healthcare, Global, M&A, Q3 2012
4.1.1 Top M&A Deals in Q3 2012
4.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals, by Therapy Area, Q3 2011 - Q3 2012
4.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Q3 2012
4.2.1 Top Initial Public Offerings in Q3 2012
4.2.2 Top Secondary Offerings in Q3 2012
4.2.3 Top PIPE Deals in Q3 2012
4.2.4 Pharmaceuticals & Healthcare, Global, Top IPOs Share Performance, Q3 2011-Q3 2012
4.2.5 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Q3 2011 - Q3 2012
4.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, Q3 2012
4.3.1 Top Venture Financing Deals in Q3 2012
4.3.2 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q3 2012
4.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q3 2012
4.3.4 Pharmaceuticals & Healthcare, Global, Venture Capital, by Therapy Area, Q3 2011 - Q3 2012
4.3.5 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Last Four Quarters
4.3.6 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Last One Year
4.3.7 Pharmaceuticals & Healthcare, Global, Private Equity Deals, Q3 2012
4.3.8 Top Private Equity Deals in Q3 2012
4.3.9 Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Q3 2011 - Q3 2012
5 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q3 2012
5.1 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q3 2012
5.2 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Q3 2011 - Q3 2012
5.3 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payments and Deal Values (US$ m), Q3 2012
5.3.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Deal Values, Q3 2012
5.3.2 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q3 2012
5.3.3 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payments, Q3 2012
5.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, by Upfront & Milestone Payments and Deal Values (US$ m), Q3 2011 - Q3 2012
5.5 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Number Of Deals, Q3 2011 - Q3 2012
5.6 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Deal Values (US$ m), Q3 2011 - Q3 2012
5.7 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), Q3 2011 - Q3 2012
6 Pharmaceuticals & Healthcare, Global, Licensing Agreements, Q3 2012
6.1 Pharmaceutical & Healthcare, Global, Licensing Agreements, Q3 2012
6.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront & Milestone Payments and Deal Values (US$ m), Q3 2011 - Q3 2012
6.2.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Deal Value, Q3 2012
6.2.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, Q3 2012
6.2.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Milestone Payment, Q3 2012
6.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Total Deal Value (US$ m), Q3 2011 - Q3 2012
6.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront Payments Vs Milestone Payments (US$ m), Q3 2011 - Q3 2012
6.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q3 2011 - Q3 2012
6.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q3 2011 - Q3 2012
6.7 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Upfront Payments Vs Milestone Payments (US$ m), Q3 2011 - Q3 2012
7 Pharmaceuticals & Healthcare, Global, M&A Financial Analysis
7.1 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value versus Median Deal Value, Q3 2011 - Q3 2012
7.2 Pharmaceuticals& Healthcare, Global Acquisitions, Average Price Earnings of Acquired Companies, Q3 2011 - Q3 2012
7.3 Pharmaceuticals & Healthcare, Global Acquisitions, Average EV/EBITDA of Acquired Companies, Q3 2011 - Q3 2012
7.4 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value per Operating Profit, Q3 2011 - Q3 2012
7.5 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share versus Average Market Price Per Share, Q3 2011 - Q3 2012
7.6 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share versus Average Book Value Per Share, Q3 2011 - Q3 2012
7.7 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Sales, Q3 2011 - Q3 2012
8 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area
8.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, Q3 2012
8.1.1 Oncology - Deals of the Quarter
8.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, Q3 2012
8.2.1 Central Nervous System - Deals of the Quarter
8.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, Q3 2012
8.3.1 Infectious Disease - Deals of the Quarter
8.4 Pharmaceuticals & Healthcare, Global, Immunology Deals, Q3 2012
8.4.1 Immunology - Deals of the Quarter
8.5 Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, Q3 2012
8.5.1 Metabolic Disorders - Deals of the Quarter
8.6 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, Q3 2012
8.6.1 Cardiovascular - Deals of the Quarter
8.7 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, Q3 2012
8.7.1 Gastrointestinal - Deals of the Quarter
8.8 Pharmaceuticals & Healthcare, Global, Hematological Disorders Deals, Q3 2012
8.8.1 Hematological Disorders - Deals of the Quarter
8.9 Pharmaceuticals & Healthcare, Global, Dermatology Deals, Q3 2012
8.9.1 Dermatology - Deals of the Quarter
8.10 Pharmaceuticals & Healthcare, Global, Respiratory Deals, Q3 2012
8.10.1 Respiratory - Deals of the Quarter
9 Deal Summary by Geography
9.1 Pharmaceuticals & Healthcare, North America Region, Deals, Q3 2012
9.1.1 North America - Deals of the Quarter
9.2 Pharmaceuticals & Healthcare, Europe Region, Deals, Q3 2012
9.2.1 Europe - Deals of the Quarter
9.3 Pharmaceuticals & Healthcare, Asia-Pacific, Deals, Q3 2012
9.3.1 Asia-Pacific - Deals of the Quarter
9.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, Q3 2012
9.4.1 Rest of the World - Deals of the Quarter
10 Pharmaceuticals & Healthcare, Global, Top Advisors
10.1 Pharmaceuticals & Healthcare, Global Top Financial Advisors, M&A, Last One Year
10.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Last One Year
11 Appendix
12 Further Information
12.1 Methodology
12.2 About GlobalData
12.3 Contact Us
12.4 Disclosure information
12.5 Disclaimer

List of Tables

1.1 List of Tables
Table 1: Pharmaceuticals & Healthcare, Global, Deal Summary, Number of Deals and Deal Values (US$m), Q3 2011 - Q3 2012
Table 2: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (%), Q3 2012
Table 3: Pharmaceuticals & Healthcare, Global, Top Deals, Q3 2012
Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012
Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, Q3 2012
Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, , Q3 2011 - Q3 2012
Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$m), Q3 2011 - Q3 2012
Table 8: Pharmaceuticals & Healthcare, Global, Top Initial Public Offering Deals, Q3 2012
Table 9: Pharmaceuticals & Healthcare, Global, Top Secondary Offering Deals, Q3 2012
Table 10: Pharmaceuticals & Healthcare, Global, Top PIPE Deals, Q3 2012
Table 11: Pharmaceuticals & Healthcare, Global, Top IPOs Share Performance, Q3 2011-Q3 2012
Table 12: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$m), Q3 2011 - Q3 2012
Table 13: Pharmaceuticals & Healthcare, Global, Venture Capital, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012
Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Capital Deals, Q3 2012
Table 15: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals and Deal Values (%), Q3 2012
Table 16: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$m), Q3 2011 - Q3 2012
Table 17: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), Q4 2011 - Q3 2012
Table 18: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Q4 2011 - Q3 2012
Table 19: Pharmaceuticals & Healthcare, Global, Private Equity, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012
Table 20: Pharmaceuticals & Healthcare, Global, Top Private Equity Deals, Q3 2012
Table 21: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$m), Q3 2011 - Q3 2012
Table 22: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012
Table 23: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012
Table 24: Pharmaceuticals & Healthcare, Partnership Deals, Upfront & Milestone Payments and Deal Values (US$ m), Q3 2011 - Q3 2012
Table 25: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront & Milestone Payments and Deal Values (US$ m), Q3 2012
Table 26: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q3 2012
Table 27: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payment, Q3 2012
Table 28: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), Q3 2011 - Q3 2012
Table 29: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q3 2011 - Q3 2012
Table 30: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payment and Deal Values (US$ m), Q3 2011 - Q3 2012
Table 31: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deal Summary, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012
Table 32: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront & Milestone Payments and Deal Values (US$ m), Q3 2011 - Q3 2012
Table 33: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Deal Values, Q3 2012
Table 34: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Total Upfront Payment, Q3 2012
Table 35: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Total Milestone Payment, Q3 2012
Table 36: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012
Table 37: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payment (US$ m), Q3 2011 - Q3 2012
Table 38: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q3 2011 - Q3 2012
Table 39: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payment and Deal Values (US$ m), Q3 2011 - Q3 2012
Table 40: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value vs Median Deal Value, (US$m), Q3 2011 - Q3 2012
Table 41: Pharmaceuticals & Healthcare, Global Acquisitions, Average P/E of Acquired Companies, Q3 2011 - Q3 2012
Table 42: Pharmaceuticals & Healthcare, Global Acquisitions, Average EV/EBITDA of Acquired Companies, Q3 2011 - Q3 2012
Table 43: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Operating Profit, Q3 2011 - Q3 2012
Table 44: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share vs Average Market Price Per Share, Q3 2009 - Q3 2012
Table 45: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share vs Average Book Value Per Share, Q3 2011 - Q3 2012
Table 46: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Sales, Q3 2011 - Q3 2012
Table 47: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012
Table 48: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012
Table 49: Pharmaceuticals & Healthcare, Global, Infectious Disease, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012
Table 50: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012
Table 51: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012
Table 52: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012
Table 53: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012
Table 54: Pharmaceuticals & Healthcare, Global, Hematological Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012
Table 55: Pharmaceuticals & Healthcare, Global, Dermatology, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012
Table 56: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012
Table 57: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012
Table 58: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012
Table 59: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012
Table 60: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012
Table 61: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), Q4 2011 - Q3 2012
Table 62: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), Q4 2011 - Q3 2012
Table 63: Pharmaceuticals & Healthcare, Deals' Key Financials, Global Acquisition Deals, Q3 2011-Q3 2012

List of Figures

1.2 List of Figures
Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$m), Q3 2011 - Q3 2012
Figure 2: Pharmaceuticals & Healthcare, Global, Number of Deals (%), Q3 2012
Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), Q3 2012
Figure 4: Pharmaceuticals & Healthcare, Global, M&A, Number of Deals and Deal Values (US$m), Q3 2011 - Q3 2012
Figure 5: Pharmaceuticals & Healthcare, Global, M&As, by Therapy Area, Number of Deals and Deal Values (US$m), by Therapy Area, Q3 2011 - Q3 2012
Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012
Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Number of Deals and Deal Values (US$m), , Q3 2011 - Q3 2012
Figure 8: Pharmaceuticals & Healthcare, Global, Venture Capital, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012
Figure 9: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals (%), Q3 2012
Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Deal Values (%), Q3 2012
Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, Q3 2011 - Q3 2012
Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), Q4 2011 - Q3 2012
Figure 13: Pharmaceuticals & Healthcare, Global, Private Equity, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012
Figure 14: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, Q3 2011 - Q3 2012
Figure 15: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012
Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012
Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront & Milestone Payment and Deal Values (US$ m), Q3 2011 - Q3 2012
Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), Q3 2011 - Q3 2012
Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q3 2011 - Q3 2012
Figure 20: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q3 2011 - Q3 2012
Figure 21: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payment and Deal Values (US$ m), Q3 2011 - Q3 2012
Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012
Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Upfront & Milestone Payment and Deal Values (US$ m), Q3 2011 - Q3 2012
Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012
Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront & Milestone Payments and Deal Values (US$ m), Q3 2011 - Q3 2012
Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Number Of Deals, Q3 2011 - Q3 2012
Figure 27: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Deal Values (US$ m), Q3 2011 - Q3 2012
Figure 28: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), Q3 2011 - Q3 2012
Figure 29: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value vs Median Deal Value, (US$m), Q3 2011 - Q3 2012
Figure 30: Pharmaceuticals & Healthcare, Global Acquisitions, Average P/E of Acquired Companies, Q3 2011 - Q3 2012
Figure 31: Pharmaceuticals & Healthcare, Global Acquisitions, Average EV/EBITDA of Acquired Companies, Q3 2011 - Q3 2012
Figure 32: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value per Operating Profit, Q3 2011 - Q3 2012
Figure 33: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share vs Average Market Price Per Share, Q3 2011 - Q3 2012
Figure 34: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share vs Average Book Value Per Share, Q3 2011 - Q3 2012
Figure 35: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Sales, Q3 2011 - Q3 2012
Figure 36: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012
Figure 37: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012
Figure 38: Pharmaceuticals & Healthcare, Global, Infectious Disease, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012
Figure 39: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012
Figure 40: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012
Figure 41: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012
Figure 42: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012
Figure 43: Pharmaceuticals & Healthcare, Global, Hematological Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012
Figure 44: Pharmaceuticals & Healthcare, Global, Dermatology, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012
Figure 45: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012
Figure 46: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012
Figure 47: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012
Figure 48: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012
Figure 49: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012
Figure 50: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), Q4 2011 - Q3 2012
Figure 51: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), Q4 2011 - Q3 2012

Order This Report


EASY ORDERING
Once you’ve selected your preferred license option, hit ‘order now’ to complete the checkout process using any major credit card, check or wire/bank transfer.
MC, Visa, AMEX, Diners, Discovery, JCB

The Fast Market Research Advantage
Only the Best
All of our research is sourced from the most trusted and established global analysts and consultancies

Client Focused
From start-ups to multinationals, we focus on providing the right research to our diverse client base

Shop Securely
Our US-based customer service team and eCommerce systems adhere to highest data security standards

Industry-leading Customer Support
Individualized assistance from our expert staff is never more than an email or phone call away


About the Publisher
GlobalData is a leading provider of global business intelligence including market, competitor, product and customer information. It provides in-depth research, analysis, data and forecasts through a range of interactive online databases, reports and management briefings. GlobalData has a large team of experienced research and analysis, consulting, and marketing experts. It has a global presence, including key offices in the US, Europe and Asia. The group has over 50 years of experience of delivering market intelligence data and analysis and a highly experienced senior management team.